Use the search parameters below to filter talks:

Calendar
Calendar

2009 - IPITA-IXA Joint Meeting (Venice)

COAGULATION DYSREGULATION AS A POTENTIAL BARRIER TO XENOTRANSPLANTATION
16 October 2009  /  08:00 - 09:15

What antiplatelet therapy should be given to the recipient?

Presenter: K. Dwyer, Melbourne, Australia

- What antiplatelet therapy should be given to the recipient?

Presenter: K. Dwyer, Melbourne, Australia

Consumptive coagulopathy and the role of extensive coagulation monitoring in xenotransplantation

Presenter: P. Simioni, Padova, Italy

- Consumptive coagulopathy and the role of extensive coagulation monitoring in xenotransplantation

Presenter: P. Simioni, Padova, Italy

PANCREAS ORGAN AND BETA CELL AVAILABILITY
12 October 2009  /  08:15 - 10:15

Donor preconditioning and pancreas recovery: dos and dont’s

Presenter: H. Arbogast, Munich, Germany

- Donor preconditioning and pancreas recovery: dos and dont’s

Presenter: H. Arbogast, Munich, Germany

PANCREAS TRANSPLANTATION: THE NEXT WAVE OF CREATIVITY
12 October 2009  /  10:45 - 13:00

Clinical research: Results of pancreas transplantation and effects of secondary complications

Presenter: A. Secchi, Milan, Italy

- Clinical research: Results of pancreas transplantation and effects of secondary complications

Presenter: A. Secchi, Milan, Italy

Risk/Benefit Ratio of PAK: Is there a case for LD kidney or SPK as the only choice?

Presenter: J. Odorico, Madison, USA

- Risk/Benefit Ratio of PAK: Is there a case for LD kidney or SPK as the only choice?

Presenter: J. Odorico, Madison, USA

The gold standard for T1D and ESRD-SPK

Presenter: H. Sollinger, Madison, USA

- The gold standard for T1D and ESRD-SPK

Presenter: H. Sollinger, Madison, USA

What does the field need for the next wave of creativity?

Presenter: D. Sutherland, Minneapolis, USA

- What does the field need for the next wave of creativity?

Presenter: D. Sutherland, Minneapolis, USA

CLINICAL ISLET TRANSPLANTATION
12 October 2009  /  14:15 - 15:45

IsIet autotransplant (IAT) outcomes after total pancreatectomy (TP) in the modern era

Presenter: D. Sutherland, Minneapolis, USA

- IsIet autotransplant (IAT) outcomes after total pancreatectomy (TP) in the modern era

Presenter: D. Sutherland, Minneapolis, USA

Improvement in outcomes of islet transplantatíon: CITR 1999-2008

Presenter: F. B. Barton, Milan, Italy

- Improvement in outcomes of islet transplantatíon: CITR 1999-2008

Presenter: F. B. Barton, Milan, Italy

Risks and benefits of transplantation in the cure of type 1 diabetes: Whole pancreas versus islet

Presenter: P. Maffi, Milan, Italy

- Risks and benefits of transplantation in the cure of type 1 diabetes: Whole pancreas versus islet

Presenter: P. Maffi, Milan, Italy

Influence of donor age on isIet isolation and transplantation outcome

Presenter: N. Niclauss, Lyon, France

- Influence of donor age on isIet isolation and transplantation outcome

Presenter: N. Niclauss, Lyon, France

Islet allograft survival with ATG induction tacrolimus and mycophenolate mofetil switching to sirolimus and mycophenolate at 6-9 months

Presenter: P. 0’Connell, , Australia

- Islet allograft survival with ATG induction tacrolimus and mycophenolate mofetil switching to sirolimus and mycophenolate at 6-9 months

Presenter: P. 0’Connell, , Australia

Immune mechanisms of teplizumab induction immunotherapy in type 1 diabetic islet allograft recipients

Presenter: P. Bansal-Pakala, Minneapolis, USA

- Immune mechanisms of teplizumab induction immunotherapy in type 1 diabetic islet allograft recipients

Presenter: P. Bansal-Pakala, Minneapolis, USA

Histological graft assessment after clinical islet transplantation

Presenter: C. Toso, Pittsburgh, USA

- Histological graft assessment after clinical islet transplantation

Presenter: C. Toso, Pittsburgh, USA

CLINICALLY RELEVANT ANTIBODIES
14 October 2009  /  10:45 - 13:00

Clinical relevance of anti-HLA antibodies

Presenter: C. Lefauchaur, Paris, France

- Clinical relevance of anti-HLA antibodies

Presenter: C. Lefauchaur, Paris, France

PIG TO PRIMATE 1
15 October 2009  /  16:00 - 18:00

Genetic modifications for pig-to-primate transplants

Presenter: A. J. d’Apice, Melbourne, Australia

- Genetic modifications for pig-to-primate transplants

Presenter: A. J. d’Apice, Melbourne, Australia

Impact of thrombocytopenia on survival of baboons with genetically-engineered pig livers

Presenter: B. Ekser, Pittsburgh, USA

- Impact of thrombocytopenia on survival of baboons with genetically-engineered pig livers

Presenter: B. Ekser, Pittsburgh, USA

Early graft failure of gtko pig organs in baboons is reduced by hCPRP expression

Presenter: A.M. Azimzadeh, Baltimore, USA

- Early graft failure of gtko pig organs in baboons is reduced by hCPRP expression

Presenter: A.M. Azimzadeh, Baltimore, USA

Hepatic function and coagulation after genetically-engineered pig liver transplantation in baboons

Presenter: B. Ekser, Pittsburgh, USA

- Hepatic function and coagulation after genetically-engineered pig liver transplantation in baboons

Presenter: B. Ekser, Pittsburgh, USA

Histopathology of wild-type and genetically-engineered pig liver xenografts in baboons

Presenter: B. Ekser, Pittsburgh, USA

- Histopathology of wild-type and genetically-engineered pig liver xenografts in baboons

Presenter: B. Ekser, Pittsburgh, USA

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi